Summary
A method has been developed for the quantitative determination of haloperidol in brain and other tissues. Such determinations have been made after acute and chronic administration of haloperidol to Sprague-Dawley rats. Different regions of the brain including the striatum, the limbic forebrain and the cerebellum have been analyzed separately. The haloperidol effects on Dopa formation have been studied in the same tissue samples. The stimulation of prolactin secretion via blockade of hypothalamic dopaminergic mechanisms and behavioural effects of the drug have been evaluated in parallel experiments.
The elimination of haloperidol from brain tissue is a multiphasic process. The fourth phase of elimination is the slowest with a half life of 4 days. No strict correlation was found between serum and brain concentrations of haloperidol. Both after acute and chronic administration there exists apparently a saturating dose above which the brain concentration of the drug increases very little. The dose seems to coincide with that beyond which little increase in Dopa formation is observed. A pharmacokinetic analysis suggests an element of saturable binding or transfer of haloperidol to brain tissue. This mechanism is not preferentially localized to areas of brain rich in dopaminergic synapses. A good correlation was found between the haloperidol concentration in the brain on the one hand and its effects on behaviour, on serum prolactin values and on Dopa formation on the other.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Andén, N.-E.: Dopamine turnover in the corpus striatum and in the limbic system after treatment with neuroleptic and anti acetylcholine drugs. J. Pharm. Pharmacol. 24, 905–906 (1972)
Andén, N.-E., Corrodi, H., Fuxe, K.: Effect of neuroleptic drugs on central catecholamine turnover assessed using tyrosine and dopamine-β-hydroxylase inhibitors. J. Pharm. Pharmacol. 24, 177–182 (1972)
Bertler, Å., Rosengren, E.: Occurrence and distribution of dopamine in brain and other tissues. Acta Physiol. Scand. 47, 350–361 (1959)
Bowers, M. B. Jr., Rozitis, A.: Regional differences in homovanillic acid concentrations after acute and chronic administration of antipsychotic drugs. J. Pharm. Pharmacol. 26, 743–745 (1974)
Braun, G. G., Poos, G. I., Soudijn, W.: Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Eur. J. Pharmacol. 1, 58–62 (1967)
Carlsson, A.: Antipsychotic drugs and catecholamine synapses. J. Psychiat. Res. 11, 57–64 (1974)
Carlsson, A.: The effect of neuroleptic drugs on brain catecholamine metabolism. In: Antipsychotic Drugs Pharmacodynamics and Pharmacokinetics (Sedvall, G., ed.), pp. 99–104. Oxford and New York: Pergamon Press 1975a
Carlsson, A.: Dopaminergic autoreceptors. In: Chemical Tools in Catecholamine Research, Vol. II (Almgren, O., Carlsson, A., and Engel, J., eds.), pp. 219–225. Amsterdam and Oxford: North.-Holl. 1975b
Carlsson, A.: Pharmacological approach to schizophrenia. In: Schizophrenia. Biological and Psychological Perspectives (Usdin, G., ed.), pp. 102–124. New York: Brunner/Mezel 1975c
Carlsson, A., Lindqvist, M.: Effect of chlorpromazine or haloperidol on formation of 3-methoxytryamine and normetanephrine in mouse brain. Acta Pharmacol. Toxicol. (Kbh.) 20, 140–144 (1963)
Carlsson, A., Lindqvist, M.: Effect of ethanol on the hydroxylation of tyrosine and tryptophan in rat brain in vivo. J. Pharm. Pharmacol. 25, 437–440 (1973)
Carlsson, A., Davis, J. N., Kehr, W., Lindqvist, M., Atack, C. V.: Simultaneous measurement of tyrosine and tryptophan hydroxylase activities in brain in vivo using an inhibitor of the aromatic amino acid decarboxylase. Naunyn-Schmiedeberg's Arch. Pharmacol. 275, 153–168 (1972)
Carlsson, A., Kehr, W., Lindqvist, M.: Agonist-antagonist interaction on dopamine receptors in brain as reflected in the rates of tyrosine and tryptophan hydroxylation. In: Advances in Parkinsonsism. Biochemistry, Physiology, Treatment (Birkmayer, W., and Hornykiewics, O., eds.). Basel: Editiones Roche 1976
Creese, I., Burt, D. R., Snyder, S.: Dopamine receptor binding: Differentiation of agonist and antagonist states with 3H-Dopamine and 3H-Haloperidol. Life Sci. 17, 993–1002 (1975)
Cressman, W. A., Bianchine, J. R., Slotnick, W. B., Johnson, P. C., Plostnieks, J.: Plasma level profile of haloperidol in man following intramuscular administration. Eur. J. Clin. Pharmacol. 7, 99–103 (1974)
Courvoisier, S., Fournel, J., Ducrot, R., Kolsky, M., Koetschet, P.: Propriétés pharmacodynamiques du chlorhydrat de chloro-3 (diméthylamino-3′ propyl) 10 phénothiazine (4560 R.P.). Arch. Int. Pharmacodyn. Ther. 92, 305–361 (1953)
Di Mascio, A.: The butyrophenones. In: Butyrophenones in Psychiatry (Di Mascio, A. and Shader, R. I., eds.), pp. 11–23. New York: Raven Press 1972
Engel, J., Carlsson, A.: Catecholamines and behaviour. In: Current Developments in Psychopharmacology (Valzelli, L. and Essman, W. B., eds.), Vol. 4, pp. 3–33. New York: Spectrum Publ. Inc. 1976
Engel, J., Liljequist, S., Johannesen, K.: Behavioural effects of long-term treatment with antipsychotic drugs, pharmacodynamics and pharmacokinetics. In: Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics (Sedvall, G., ed.), pp. 63–71. Oxford and New York: Pergamon Press 1975
Forsman, A., Öhman, R.: On the pharmacokinetics of haloperidol. Nordisk psykiatrisk tidskrift 28, 441–448 (1974)
Forsman, A., Öhman, R.: Some aspects of the distribution and metabolism of haloperidol in man. In: Antipsychotic Drugs, Pharmacodynamics and Pharmacokinetics (Sedvall, G., ed.), pp. 359–365. Oxford and New York: Pergamon Press 1975
Forsman, A., Öhman, R.: Pharmacokinetic studies on haloperidol in man. Curr. Ther. Res. 20, 319–336 (1976)
Forsman, A., Mårtensson, E., Nyberg, G., Öhman, R.: A gaschromatographic method for determining haloperidol. Naunyn-Schmiedeberg's. Arch. Pharmacol. 286, 113–124 (1974)
Janssen, P. A. J., Allewijn, F. T. N.: The distribution of the butyrophenones haloperidol, trifluperidol, moperone and clofuperol in rats and its relationship with their neuroleptic activity. Arzneim.-Forsch. 19, 199–206 (1969)
Jansson, P. A. J., Soudijn, W., van Wijngaarden, I., Dresse, A.: Pimozide, a chemically novel highly potent and orally long-acting neuroleptic drug. Part III. Regional distribution of pimozide and haloperidol in the dog. Arzneim.-Forsch. 18, 282–287 (1968)
Kehr, W., Carlsson, A., Lindqvist, M.: A method for the determination of 3,4-dihydroxyphenylalanine (Dopa) in brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 274, 273–280 (1972a)
Kehr, W., Carlsson, A., Lindqvist, M., Magnusson, T., Atack, C.: Evidence for a receptor mediated feedback control of striatal tyrosine hydroxylase activity. J. Pharm. Pharmacol. 24, 744–747 (1972b)
Kehr, W., Carlsson, A., Lindqvist, M.: Biochemical aspects of dopamine agonists. In: Advances in Neurology (Calne, D. B., Chase, T. N., and Barbeau, A., eds.), Vol. 9, pp. 185–195. New York: Raven Press 1975
Lewi, P., Heykants, P., Allewijn, F., Dony, J., Janssen, P.: Distribution and metabolism of neuroleptic drugs. Arzneim.-Forsch. 20, 943–948 (1970)
McNeilly, A.: Radioimmunoassay of human prolactin. Proc. R. Soc. Med. 66, 863–864 (1973)
Meltzer, H., Daniels, S., Fang, V.: Clozapine increases rat serum prolactin levels. Life Sci. 17, 339–342 (1975)
Nybäck, H., Sedvall, G.: Effect of chlorpromazine on accumulation and disappearance of catecholamines formed from tyrosine 14C in brain. J. Pharmacol. Exp. Ther. 162, 294–301 (1968)
Sjöqvist, F., Alexandersson, B., Åsberg, M., Bertilsson, L., Borgå, O., Hamberger, B., Tuck, D.: Pharmacokinetics and biological effects of nortriptyline in man. Acta Pharmacol. Toxicol. (Kbh.) 29, Suppl. 3, 255–280 (1971)
Soudijn, W., van Wijngaarden, I., Allewijn, F.: Distribution, excretion and metabolism of neuroleptics of the butyrophenone type. Eur. J. Pharmacol. 1, 47–57 (1967)
Turkington, R. W.: Prolactin secretion in patients treated with various drugs. Arch. Intern. Med. 130, 349–354 (1972)
Wiesel, F. A., Sedvall, G.: Effect of antipsychotic drugs on homovanillic acid levels in striatum and olfactory tubercle of the rat. Eur. J. Pharmacol. 30, 364–367 (1975)
Winnik, H. Z., Tennenbaum, L.: Aparation de galactorrhea an cours du traitment de largactil. Presse Med. 63, 1092 (1955)
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Öhman, R., Larsson, M., Nilsson, I.M. et al. Neurometabolic and behavioural effects of haloperidol in relation to drug levels in serum and brain. Naunyn-Schmiedeberg's Arch. Pharmacol. 299, 105–114 (1977). https://doi.org/10.1007/BF00498552
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00498552